Venkat Reddy, MD
Family Practice · Nashville, TNNPI 1720134521
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Abbott at 38.1% of the total. Reporting peaked in 2022 at $1,322 and has fallen 60.4% since, to $523 in 2025. Among family practice clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $28.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AstraZeneca$698
- Medtronic$627
- Indivior Inc.$282
- Novo Nordisk$273
- Lilly USA, LLC$221
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,845100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 44 | $2,231 |
| AstraZeneca | 41 | $698 |
| Medtronic(2 entities) | 7 | $627 |
| Indivior Inc. | 11 | $282 |
| Novo Nordisk | 15 | $273 |
| Lilly USA, LLC | 11 | $221 |
| Atricure, Inc. | 1 | $196 |
| Astellas Pharma US Inc | 10 | $184 |
| Shield Therapeutics Inc | 7 | $130 |
| Johnson & Johnson | 7 | $128 |
| GSK | 8 | $117 |
| Pfizer | 6 | $96 |
| AbbVie | 4 | $89 |
| Lundbeck LLC | 4 | $66 |
| Exact Sciences | 3 | $52 |
| Braeburn Inc. | 2 | $52 |
| Amgen | 3 | $51 |
| Alkermes, Inc. | 2 | $49 |
| Merck | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Novartis | 2 | $37 |
| UCB, Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $24 |
| Werfen USA LLC | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| SK Life Science, Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epic$461
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$196
- Mosaic$164
- 3F$155
- CoreValve Evolut$110
- SUBLOCADE$105
How this compares
$5,851 in reported general payments places this provider in the 95th percentile of 184 family practice providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 46 | $47,809 |
| OzempicSemaglutide | 23 | $37,830 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $29,523 |
| JardianceEmpagliflozin | 25 | $27,373 |
| EliquisApixaban | 32 | $23,365 |
| XareltoRivaroxaban | 14 | $15,505 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,876 |
| EntrestoSacubitril/Valsartan | 11 | $7,117 |
| Divalproex Sodium | 52 | $2,820 |
| Entacapone | 53 | $1,877 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,461 |
| Potassium Chloride | 71 | $1,354 |
| Oxcarbazepine | 106 | $1,175 |
| Atorvastatin Calcium | 190 | $1,096 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $698 | $47,80946 claims |
| Novo NordiskOzempic | $273 | $37,83023 claims |
| GSKTrelegy Ellipta | $117 | $29,52319 claims |
| Boehringer IngelheimJardiance | $24 | $27,37325 claims |
| PfizerEliquis | $96 | $23,36532 claims |
| Johnson & JohnsonXarelto | $128 | $15,50514 claims |
| NovartisEntresto | $37 | $7,11711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 184 family practice providers in Tennessee.
Other family practice in Nashville
- Ryan HammondNashville$90
- Chelsea LinNashville$81
- Cecily Montgomery-ImaniNashville$0
- Aleksandra FryeNashville$0
- Amanda OlsonNashville$0
- Kellee TaylorNashville$0
- Lynn HollidayNashville$0
- Andrew GibbsNashville$0
- Jean DavisMilan$2K
- Anna JacksonMemphis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.